Dr. Brittany Wright, PharmD, BCACP
Assistant Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Wright is an ambulatory care trained pharmacist who previously developed clinical pharmacy services within outpatient pediatric and adult cystic fibrosis and pulmonology clinics. Clinically, her research interests include cystic fibrosis, asthma, non-CF bronchiectasis, rare lung disease, insurer/payer systems, and medication access. Dr. Wright also has an interest in interdisciplinary education and training.
Education: Pharm.D., University of Iowa College of Pharmacy (2014); PGY1 Pharmacy Practice Residency, University of Iowa Health Care (2015); PGY2 Ambulatory Care Residency, University of Iowa Health Care (2016)
Awards and Honors: Senior Merck Award, University of Iowa College of Pharmacy (2014); Professional Experience Program Exemplary Performance in Advanced Pharmacy Practice Experiences Award, University of Iowa College of Pharmacy (2014); Volunteer Services 1,000 Hour Recognition, University of Iowa Health Care (2013); Pharmacy Residency Preceptor of the Year, University of Iowa Health Care (2022)
Leadership Experience: North American Cystic Fibrosis Conference Abstract Review Committee, CFF (2019 to Present); Implementation of Outpatient Pharmacy Services Grant Review Committee, CFF (2019 to Present); Education Committee, CFF (2022 to 2025 North American Cystic Fibrosis Conference Pharmacy Session Co-Chair, CFF (2021); Financial Wellness Advisory Committee, CFF (2023 to Present); Access Steering Committee, CFF (2023 to 2024), North American Cystic Fibrosis Conference Pharmacy Session Co-Chair, CFF (2023); Pharmacist and Social Work Collaboration Focus Group, CFF (2024); CF-PHARM (Cystic Fibrosis Pharmacy/Clinical Pharmacology Alliance for Research and Collaboration) Co-Production of Medication Management Co-Lead, Cystic Fibrosis Foundation (CFF) (2024 to Present)
- Pharmacy Practice Co-Chair (SPPS 201)
- Bruch B, Singh S, Ramsey L, Starner T. Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients. Pediatric Pulmonology 2018. DOI: 10.1002/ppul.24024
- McKinzie C, Chen L, Ehlert K, Grisso A, Linafelter A, Lubsch L, O’Brien C, Pan A, Wright B, Elson E. Use of intravenous antimicrobials for inhalation in patients with cystic fibrosis. Pediatric Pulmonology 2019. DOI: 10.1002/ppul.24511
- Wright B, Singh S, Schultz L, Ramsey L, Spading K, Mascardo L, Starner T. Impact of pharmacy services on cystic fibrosis transmembrane conductance regulator (CFTR) modulator prescribing at a pediatric cystic fibrosis center. Pediatric Pulmonology 2019. DOI: 10.1002/ppul.24446
- Wright B, Ketchen N, Rasmussen L, Bartels A, Singh S. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients. Pediatric Pulmonology 2021. DOI: 10.1002/ppul.25781
- Flynn H, Wright B, Larson Ode K. Assessing the occurrence of reproductive health counseling in adolescents with cystic fibrosis. Pediatric Pulmonology 2022. DOI: 10.1002/ppul.26196
- Beck MR, Hornick DB, Pena TA, Singh SB, Wright BA. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatric Pulmonology 2023. DOI: 10.1002/ppul.26362
- Pena TA, Wright BA, Parekh KR, Klesney-Tait J. Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States. The Journal of Heart and Lung Transplantation 2024. DOI: 10.1016/j.jhlto.2024.100171
- Steimel E, Bayer DK, Wright BA, Hinds DM. Little lungs, big relief: Dupilumab in a 2-year-old with severe persistent asthma. Pediatric Pulmonology 2024. DOI: 10.1002/ppul.27058
- Wright BA, Andrade LM, Dumitrescu AV, Larson SA, Weiner RL, Kemp PS. A new vision: Integration of ophthalmology services into an interdisciplinary pediatric cystic fibrosis clinic model. Pediatric Pulmonology 2024. DOI:10.1002/ppul.26912
- Wright BA, Godfrey KC, Gryp EE, Harklau NM, Colsch LB. Fueling health: Overcoming food barriers in cystic fibrosis care. Pediatric Pulmonology 2025. DOI: 10.1002/ppul.71177
- Evaluate real-world effectiveness and safety of CFTR modulators in diverse patient populations, including those with rare mutations or comorbidities.
- Lead medication adherence and optimization studies, leveraging digital health tools, pill count data, refill patterns, or therapeutic drug monitoring.
- Develop pharmacist-led clinical interventions (e.g., MTM services, adherence coaching, patient education) and study their impact on health outcomes and quality of life in CF and pulmonary patients.
- Explore strategies for care of aging CF populations with an emphasis on reproductive health and chronic disease management.
- Investigate barriers to medication access, including formulary restrictions, copay burden, and specialty pharmacy use, and propose system-level solutions.
- Examine transitions of care (e.g., pediatric to adult CF care or hospital to home) and the pharmacist's role in ensuring continuity and medication reconciliation.